Pricing Strategy Diagnostic: The 90-Day Checklist PE Operators Use

A pricing strategy document is not the same as a pricing strategy. One exists in a folder. The other shows up in your closed-won data. If you have not run a structured diagnostic in the last 12 months, you do not know which one you actually have.

This checklist walks through the six diagnostic areas that matter most for B2B SaaS companies at $10M to $150M annual recurring revenue (ARR). Work through each one systematically. The gaps you find will tell you where to focus.

The True Bill

Undiagnosed pricing problems are expensive in a specific way: they are quiet. You are still closing deals. You are still growing ARR. The drag is invisible because you do not have the counterfactual.

A SaaS company at $45M ARR running a 22% average discount rate that tightens to 12% through a focused 90-day intervention adds roughly $4.5M in realized revenue without changing a line of code or a word of their positioning. That delta compounds at renewal. A $4.5M gain in year one becomes a $5.1M gain in year two as the cleaner deal structures enter their first renewal cycle.

The cost of not running the diagnostic is not abstract. It is calculable.

Execution

Area 1: Tier and value metric clarity

• Can your five most junior AEs explain why each tier is priced the way it is?
• Is your value metric (seats, usage, outcomes) aligned to how buyers measure ROI?
• Has your value metric been reviewed in the last 18 months as your product has evolved?

Area 2: Pocket price waterfall

• Do you have a documented view of every concession type applied between list and invoice?
• Is each concession type tracked in your CRM or deal desk system?
• Is there a named owner responsible for concession reporting?

Area 3: Discount governance

• Is there a written discount policy, including floor prices and escalation thresholds?
• Is the discount policy enforced in CRM (approval gates, not just written rules)?
• What was your average discount rate 12 months ago versus today?

Area 4: Renewal pricing behavior

• Are renewals negotiated from a fresh pricing basis or from the original deal structure?
• What percentage of renewals include a price increase?
• What is your average price increase rate at renewal?

Area 5: Competitive pricing position

• Do you have a documented view of where you sit versus your three closest competitors?
• Is that view based on actual deal data or marketing assumptions?
• Has your competitive pricing position shifted in the last 12 months?

Area 6: Sales team pricing confidence

• When did you last train your AEs on the commercial logic behind your pricing?
• Can your reps defend your pricing floor in a procurement conversation without manager support?
• What is the most common pricing objection your team hears, and what is the approved response?

Where It Unravels

A $38M ARR SaaS company in the fintech space had not run a pricing diagnostic since their Series A two years prior. Their CPO owned pricing. Their VP of Sales owned deal approval. Their CFO owned revenue targets. Nobody owned the commercial health of the pricing model end-to-end.

The diagnostic found six distinct leakage points in their pocket price waterfall. Three of them had been present since the original pricing design and were never intended to be permanent. Together they represented 14% of potential ARR.

Before diagnostic: $38M ARR, 14% average discount (stated), effective realized rate after all concessions: $32.7M. Nine months post-remediation: $44M ARR, 9% average discount, effective realized rate: $40M.

The gap between stated and realized revenue was the most important number in the business. Nobody had measured it.

Move This Week

Pick one checklist area from above and audit it today using your CRM data. Do not try to run all six at once. The area with the most "no" answers in the next 30 minutes is your highest-priority commercial gap.

When did you last know your effective realized revenue per customer, not your contracted ARR?

Assess Your Commercial Health to benchmark your pricing strategy against similar-stage companies.